scispace - formally typeset
E

Ezra E.W. Cohen

Researcher at University of California, San Diego

Publications -  436
Citations -  30605

Ezra E.W. Cohen is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Head and neck squamous-cell carcinoma & Cancer. The author has an hindex of 70, co-authored 399 publications receiving 25545 citations. Previous affiliations of Ezra E.W. Cohen include University of Chicago & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Comprehensive genomic characterization of head and neck squamous cell carcinomas

Michael S. Lawrence, +309 more
- 29 Jan 2015 - 
TL;DR: It is shown that human-papillomavirus-associated tumours are dominated by helical domain mutations of the oncogene PIK3CA, novel alterations involving loss of TRAF3, and amplification of the cell cycle gene E2F1.
Journal ArticleDOI

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, +107 more
- 12 Jan 2019 - 
TL;DR: The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of p embrolizUMab as a monotherapy and as part of combination therapy in earlier stages of disease.
Journal ArticleDOI

Cabozantinib in Progressive Medullary Thyroid Cancer

Rossella Elisei, +18 more
- 10 Oct 2013 - 
TL;DR: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.
Journal ArticleDOI

PI3Kγ is a molecular switch that controls immune suppression

Megan M. Kaneda, +23 more
- 17 Nov 2016 - 
TL;DR: This work demonstrates that therapeutic targeting of intracellular signalling pathways that regulate the switch between macrophage polarization states can control immune suppression in cancer and other disorders.